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We retrospectively evaluated the outcome of reducedintensity conditioning (RIC) followed by allogeneic hematopoietic stem cell transplantation (HCT) in 43 patients with myelodysplastic syndrome (MDS) or AML arising from MDS. All patients received fludarabine plus melphalan followed by an allogeneic HCT from an HLA-identical sibling (SIB: n ¼ 19) or unrelated donor (MUD: n ¼ 24). Median age was 58 years (range: ). Diagnoses at transplantation were RA (n ¼ 8), RARS (n ¼ 1), RAEB (n ¼ 13), RAEB-T (n ¼ 6), or AML arising from MDS (n ¼ 15). Of 28 patients with MDS, two patients had low, 10 had intermediate-1, nine had intermediate-2 and seven had high-risk MDS by IPSS criteria. All patients initially engrafted with the median neutrophil recovery of 15 days (range: 9-27). The 2-year overall survival, disease-free survival, relapse and transplant-related mortality were 53.5% (CI 45.2-61.1), 51.2% (CI 43.3-58.5), 16 .3% (CI 7.9-30.7) and 35.2% (26.4-45.7) , respectively. Grade II-IV acute graft-versushost disease occurred in 27 (63%) patients. There was no significant survival difference between SIB and MUD-HCT, but the relapse rate was higher among SIB donor recipients when compared to MUD (38.5 versus 7%,
Introduction
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem-cell disorders characterized by ineffective dysplastic hematopoiesis involving one or more cell lineages, peripheral-blood cytopenias and a high risk of progression to AML. 1 Allogeneic hematopoietic stem cell transplantation (HCT) is the only potentially curative treatment at present for MDS, replacing recipient dysplastic hematopoiesis with healthy donor hematopoiesis and immune system with a potential GVL effect. Allogeneic HCT has been, however, limited to younger patients due to the increased risk of regimen-related toxicities and GVHD. Conventional myeloablative allogeneic HCT is associated with a relapse rate ranging from 28 to 48% and a substantial non-relapse mortality ranging from 34 to 54%, with transplant-related complications increasing in frequency and severity with age. [2] [3] [4] [5] As the majority of patients with MDS are of advanced age, with only about 25% of patients younger than 60 years, 6, 7 often with concurrent medical conditions, many of them are excluded from a myeloablative allogeneic HCT.
Over the last several years, reduced-intensity conditioning (RIC) regimens have been demonstrated to be safe and efficacious in a wide range of hematologic malignancies. [8] [9] [10] [11] [12] However, its efficacy in MDS has not been fully understood as the majority of studies using RIC evaluated combined cohorts of both MDS and AML [13] [14] [15] [16] [17] [18] with relatively short follow-up. The intensity of the preparative regimen has been shown to directly influence relapse incidence and leukemia-free survival after allografting for AML and MDS.
14 Van Besien and colleagues 17 studied a conditioning regimen of fludarabine, melphalan and alemtuzumab for AML (n ¼ 41) and MDS (n ¼ 11). The results of this study showed a progression-free survival (PFS) rate of 38% at 1 year. However, for high-risk patients (MDS45% blasts or active AML), the PFS was only 25% at 1 year. Using the same conditioning regimen, Tauro and colleagues 18 reported a 3-year disease-free survival (DFS) probability of 37% for the entire cohort (AML/MDS) and 34% (at 3 years) for MDS patients alone. The primary cause of treatment failure in this study was relapse. Similarly, Ho and colleagues 16 reported outcomes on 62 patients with MDS (n ¼ 35), chronic myelomonocytic leukemia (n ¼ 4), or AML with trilineage dysplasia (n ¼ 23) who underwent RIC-HCT using fludarabine, busulfan and alemtuzumab. The overall survival (OS) and DFS at 1 year were 73 and 61%, respectively, but the incidence of relapse was high; 50% for AML and 80% for MDS patients with high-risk IPSS (International Prognostic Scoring System). These studies suggest that the intense degree of T cell depletion achieved by alemtuzumab may be associated with increased risk of relapse post-allogeneic HCT.
In this study, we sought to characterize the level of disease control and overall outcome of patients with MDS who underwent RIC-HCT using melphalan plus fludarabine without T cell-depleting antibodies.
Patients and methods

Patients
In this retrospective analysis, we studied outcomes in a consecutive case series of 43 patients diagnosed with either MDS or AML arising from prior MDS who underwent a RIC-HCT from an HLA-identical sibling or unrelated donor using fludarabine and melphalan between September 2000 and December 2004. In accordance with institutional review board guidelines, a waiver of written informed consent was obtained for this retrospective chart review. A diagnosis of MDS and its subtype was based on peripheral blood and bone marrow morphology immediately before the transplant. We excluded chronic myelomonocytic leukemia from this analysis.
Donors and stem cell source
High-resolution polymerase chain reaction-sequencespecific-primers for HLA class I and II was performed as described previously. 19 All were 6/6 matches with the exception of four unrelated donors who had one antigen mismatch. Four patients received a bone marrow graft and the remaining 39 patients received a GCSFmobilized PBSC graft with a median CD34 þ cell dose at 5.86 Â 10 6 /kg (range: 0.53-30.0).
Preparative regimen and GVHD prophylaxis
All patients received fludarabine 25 mg/m 2 intravenously (i.v.) daily for 5 days, followed by melphalan 140 mg/m 2 i.v. for conditioning. GVHD prophylaxis consisted of cyclosporine (CSP) þ mycophenolate mofetil (MMF) for sibling donor transplants throughout the study period and for MUD until December 2002. Thereafter, a short course of MTX was added to the regimen for MUD recipients. CSA was given at 3 mg/kg i.v. on day À1 and switched to an oral dose of approximately three times i.v. dose when oral intake was resumed. One patient with a history of systemic lupus erythematosus (SLE) and renal insufficiency received tacrolimus (FK506) instead of CSA as recommended by nephrology. MMF was given at 15 mg/kg i.v. three times a day beginning on day 0, switched to the same oral dose when oral intake is resumed. MTX was given at 10 mg/m 2 i.v. on day þ 1, and 5 mg/m 2 on days þ 3 and þ 6.
Supportive care
Supportive care, including prophylactic antibiotics, antifungal therapy, total parenteral nutrition, hematopoietic growth factors, immune globulin replacement and treatment of mucositis and neutropenic fever was administered in accordance with institutional standard practice guidelines. 20 Surveillance blood cultures for cytomegalovirus were monitored twice weekly between day þ 21 and þ 100 post-HCT, and patients received pre-emptive ganciclovir at onset of cytomegalovirus viremia.
Serial samples of peripheral blood or bone marrow were monitored for hematopoietic chimerism by using polymerase chain reaction-based analyses of variable number tandem repeats. 21 
Statistical methods
Demographic, disease and treatment characteristics for all patients were summarized using descriptive statistics. Survival estimates were calculated based on the productlimit method, 22 and 95% confidence intervals were calculated using the logit transformation and the Greenwood variance estimate. 23 Transplant-related mortality (TRM) was defined as meeting both the criteria of 'no relapse or persistent disease' and death due to non-relapse causes. Differences between survival curves were assessed by the log-rank test. Cumulative incidence estimates were used to summarize the probability of relapse and TRM. Relapse was regarded as a competing risk for TRM and death without relapse as a competing risk for relapse. The significance of features present at diagnosis and at HCT was assessed by univariate Cox regression analysis. 24 The list of features in this analysis included previously identified factors associated with overall and/or disease-free survival in MDS/AML patients treated with conventional chemotherapy or allo-HCT. Disease relapse was defined as progression of MDS from the best response. One patient who relapsed with Hodgkin's lymphoma 23 months post transplant was not counted as a relapse of MDS in this study. Risk factors analyzed included patient age at transplant (above or below median), donor type (SIB versus MUD), patient gender, donor-patient gender match (female to male versus other combinations), de novo or secondary MDS, prior autologous transplant, IPSS/disease status (Low/Int-1 versus Int-2/high versus AML from MDS), blood and bone marrow blast %, HLA match degree (6/6 versus 5/6), Karnofsky performance status (KPS o90 versus X90%), recipient CMV serostatus, acute GVHD, CD34 þ cell dose (above or below median) and cytogenetic risk.
Results
Patients
Patient and transplant characteristics are summarized in Table 1 . All patients were either of advanced age and/or possessed undesirable risk factors to conventional myeloablative HCT (Table 1) . Twenty-three patients were older than 55 years old (31 patients X50 year old). Eleven patients had a prior autologous HCT (five for nonHodgkin's lymphoma, two for Hodgkin's lymphoma, one for myeloma and four for AML/MDS). Other co-morbid conditions included active infection, history of alcohol abuse, reduced pulmonary functions, chronic hepatitis B or C, SLE with reduced creatinine clearance, diabetes and prior history of adult respiratory distress syndrome with renal insufficiency.
According to the International Prognostic Scoring System, 7 
Prior induction therapy
Of the 28 MDS patients, four received induction chemotherapy before transplant (Table 2) ; only one of these four patients remained in remission at the time of admission for HCT. Of the 15 patients with AML arising from preceding MDS, induction therapy was given to 13 patients including five patients who received an additional cycle of consolidation therapy. Of these, eight were in remission and five had evidence of leukemia including one with persistent cytogenetic abnormalities despite morphologic remission. The overall CR rate in 17 patients who received pretransplant induction was 52.9% (9 of 17). At the time of transplant, 34 of 43 patients (79%) had persistent MDS or AML: 27 MDS (24 untreated, three induction failure) and seven AML arising from MDS (two untreated, five induction failure).
Engraftment
Except for one patient who died very early, all patients engrafted with the median neutrophil recovery (4500/ml) at day 15 (range: 9-27). Engraftment analysis using STR was available in 36 patients around day þ 30 post transplant, demonstrating 100% donor chimerism in 26 and X89% donor chimerism in the remaining 10 patients. The median absolute lymphocyte counts on day 30 was 500/ml (range: 70-2240/ml). One MUD recipient developed secondary graft failure about 3 months post-HCT with no evidence of disease at that time, following withdrawal of immunosuppression for earlier AML relapse.
Initial disease control
Nine patients had no post transplant bone marrow studies because of early deaths or serious complications early post transplant. Of the remaining 34 patients, 31 (91%) showed no evidence of residual MDS by morphology or cytogenetics in a follow-up bone marrow performed at the median of 32.5 days (range: 24-52) post transplant.
Focusing on patients with persistent MDS (n ¼ 27) or persistent AML (n ¼ 7) at the time of transplant, an early post transplant bone marrow examination was available in 27 (MDS: 21, AML: 6). Of these, twenty-four patients (89%) showed no evidence of MDS or AML around day þ 30 by bone marrow morphology and cytogenetics/FISH. Three patients had evidence of persistent disease including one with only a clonal cytogenetic abnormality without morphologic evidence for AML/MDS.
Overall outcomes
Of 43 patients, 20 are alive after a median follow-up of 38 months (range: 24-67 months). Seven deaths occurred in a setting of relapsed or progressive MDS/AML. Non-relapse mortality in the remaining 16 patients was attributable to infection/multi-organ failure associated with severe acute GVHD (n ¼ 11) or extensive chronic GVHD (n ¼ 1). Two patients without GVHD died before day þ 100 due to respiratory failure attributable to regimen-related toxicity and one patient died of secondary graft failure. The two late deaths (3 and 4 year post-HCT) were attributable to infections in the face of extensive chronic GVHD. The 100-day TRM was 27.4% (18.7-38.9) while two-year TRM was 35.2% (CI 26.4-45.7). The 2-year overall survival, disease- Table 2 Induction therapy and disease status before transplant
7+3 (5+2): standard infusional cytarabine Â 7 days plus idarubicin (or daunorubicin) Â 3 days (5+2: 5 days and 2 days of cytarabine and idarubicin, respectively), HDAC (high-dose cytarabine). 
Risk factor analysis
In univariate analysis, there was a trend toward better OS among patients who received higher CD34 þ cell doses (X5.9 Â 10 6 /kg versus o5.9 Â 10 6 /kg: median for the entire cohort) with the 2-year OS probabilities of 66.7 versus 40.9% respectively (P ¼ 0.16). There was no significant difference in OS or DFS according to IPSS/disease status (Figure 2 ) or cytogenetics.
While there was no significant survival difference between related (SIB) and unrelated (MUD) donors (the 2-year OS probabilities were 47.4% for SIB and 58.3% for MUD, P ¼ 0.64: Figure 3a) , the risk of relapse was significantly lower in MUD when compared to SIB (6.7 versus 38.5%, P ¼ 0.02) by univariate analysis (log-rank: Figure 3b ). Owing to the baseline differences in cytogenetic risk and CD34 þ cell dose between MUD and SIB, Cox regression analysis was then adjusted to these factors. After adjusting for these factors, there remained a trend for lower relapse in MUD compared with SIB (HR: 0.11, Reduced-intensity transplant for MDS R Nakamura et al CI 0.01-1.08, P ¼ 0.06) ( Table 3 ). There was no statistically significant difference in TRM between SIB and MUD with the probabilities at 2 years at 31.6 versus 37.5% respectively (P ¼ 0.44). None of the other pretransplant clinical factors adjusted for the cytogenetic risk and CD34 þ cell dose were found to be significantly associated with OS, DFS or relapse in this case series (Table 3) . As expected, however, severe GVHD (grade III-IV) was associated with poorer OS and DFS.
Discussion
We have previously reported the safety and feasibility of RIC using fludarabine and melphalan for patients with a prior history of autologous HCT 25 and for MUD transplants. 26 In the current study focusing on MDS patients, transplant-related mortality and GVHD were comparable to the overall RIC-HCT experience in our institution. The 2-year OS of 53% and DFS of 51% in our case series compare favorably with the results from fullintensity conditioning HSCT including our own historic data with busulfan plus cyclophosphamide conditioning. 27 Sierra et al. 28 on behalf of the International Bone Marrow Transplant Registry (IBMTR), reported results in 452 patients with MDS transplanted from HLA-identical siblings. Three-year TRM, relapse, DFS and OS rates were 37, 23, 40 and 42%, respectively. Data from the National Marrow Donor Program reported the estimated DFS probability for patients with MDS to be 29% in 510 patients at 2 years. 5 Deeg and colleagues 29 recently reported the results of targeted busulfan and cyclophosphamide as conditioning for MDS with improved outcome for low-risk MDS (RA, RARS). However, the 3-year RFS among patients with advanced disease (RAEB and RAEB-T/t-AML) were still unsatisfactory at 40 and 29%, respectively.
Our results showed that durable disease control could be achieved using fludarabine and melphalan for high-risk MDS including RAEBT, therapy-related MDS, and AML arising from MDS. Marrow evaluation 1-2 months post-HCT showed no evidence of MDS in 25 of 28 evaluable patients (89%) with documented disease pre-HCT, suggesting an effective eradication of MDS clones by the conditioning and by rapid engraftment of donor hematopoiesis. A low relapse rate after a relatively long follow-up period in this case series also suggests that a GVL effect can be expected in the RIC-HCT setting. Of note, there was a trend for lower relapse rate in MUD compared with SIB in multivariate analysis, which suggests a greater GVL effect linked to a greater antigen disparity in MUD. However, the reduced risk of relapse did not extend to a better OS. Although we observed no significant difference in TRM between SIB and MUD, it is likely that the MUD transplants are associated with higher TRM without reaching a statistical significance due to the size of this study. Our findings contrast with earlier reports using alemtuzumab as part of RIC, in which relapse was the primary cause of treatment failure. 17, 18 Although no definitive conclusion can be made from our study of a relatively small and heterogeneous patient population, it is possible that the intense degree of T cell depletion achieved using alemtuzumab would increase the risk of relapse. On the other hand, we experienced relatively high incidence of severe GVHD using cyclosporine plus MMF, which contributed to a majority of non-relapse deaths. Thus, effective prevention of GVHD without increasing the risk of relapse continues to be a major challenge in RIC-HCT for MDS.
The role of pretransplant remission induction therapy for MDS is not well defined, 30 particularly for RIC-HCT. While induction therapy may potentially improve disease control, it is associated with a lower remission rate and higher morbidity and mortality in this group of patients. A significant proportion of patients may become ineligible for a potentially curative option of allogeneic HCT due to morbidity from such chemotherapy. In an above-mentioned study by Ho and colleagues (2004) , all patients (n ¼ 62) had received at least one prior course of chemotherapy, except for 16 patients with refractory anemia/cytopenia. While truly non-myeloablative regimens or RIC using T cell-depleting antibodies may require induction chemotherapy to allow sufficient time for a GVL to become effective, it did not appear critical in our regimen that was associated with a low relapse rate. In our cohort, only 4 of 19 patients with RAEB or RAEBT received pretransplant induction. However, it should be noted that our analysis was not designed to address the role of pretransplant induction therapy for MDS. Newer agents, such as 5-azacitidine and decitabine, are increasingly used for treatment of MDS. The influence of pretreatment with these demethylating agents before HCT remains to be studied.
In summary, RIC-HCT with fludarabine plus melphalan was associated with acceptable toxicity and durable disease control in our high-risk MDS cohort. Efforts to further improve outcome of these patients are underway including tacrolimus plus sirolimus for GVHD prophylaxis and novel conditioning regimens incorporating radioimmunotherapy and/or clofarabine.
